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ABSTRACT 
 
 
Objectives: Several studies have suggested a positive association between serum lipid 
levels and blood pressure (BP). This study investigated this association in a large population 
from 12 European countries. 
 
Methods: Data were taken from the European Study on Cardiovascular Risk Prevention and 
Management in Usual Daily Practice (EURIKA; ClinicalTrials.gov identifier: 
NCT00882336). Associations between BP and lipid levels in patients free from 
cardiovascular disease (CVD) and with at least one major CVD risk factor (N = 7641) were 
assessed using linear regression analyses. 
 
Results: Overall, 72.8% and 64.8% of patients had hypertension and dyslipidaemia, 
respectively; 47.0% had both conditions. Regression coefficients (95% confidence interval 
[CI]) for the associations of low-density lipoprotein cholesterol, non-high-density 
lipoprotein cholesterol, total cholesterol and apolipoprotein B levels with systolic BP, 
adjusted for age, sex and body mass index, were 0.93 mmHg/mmol/L (0.54 to 1.31), 1.07 
mmHg/mmol/L (0.73 to 1.40), 1.02 mmHg/mmol/L (0.69 to 1.35) and 4.94 mmHg/g/L (3.43 
to 6.46), respectively. The corresponding values (95% CI) for the associations with diastolic 
BP were 0.96 mmHg/mmol/L (0.73 to 1.19), 0.95 mmHg/mmol/L (0.75 to 1.15), 0.87 
mmHg/mmol/L (0.67 to 1.07) and 4.33 mmHg/g/L (3.42 to 5.23), respectively. Most of 
these associations remained significant whether patients were treated with statins or not. 
 
Conclusions: Small but statistically significant associations between lipid levels and BP were 
observed in a large, multinational European population. Further research is warranted to 
assess the causality of this association and its implications on the management of patients 
with both hypertension and dyslipidaemia. 
 
 
Keywords: blood pressure, cholesterol, dyslipidaemia, hypertension 
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Abbreviations 
 
ACE, angiotensin-converting enzyme; apo-A1, apolipoprotein A1; apo-B, apolipoprotein B; 
AT1, angiotensin II type 1; BMI, body mass index; BP, blood pressure; CHD, coronary heart 
disease; CI, confidence interval; CVD, cardiovascular disease; DBP, diastolic blood 
pressure; EURIKA, European Study on Cardiovascular Risk Prevention and Management in 
Usual Daily Practice; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 
lipoprotein cholesterol ; SBP, systolic blood pressure 
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INTRODUCTION 
 
 
Dyslipidaemia and hypertension are two of the principal, established, modifiable risk factors 
for cardiovascular disease (CVD) and coexist in a substantial proportion of patients [1-3]. It 
has also been shown that the coronary heart disease (CHD) risk in patients with hypertension 
and dyslipidaemia is greater than the sum of CHD risks for hypertension and dyslipidaemia 
when they occur alone [4], thereby supporting a degree of clinical interaction between the 
two risk factors. Despite recent improvements in the understanding and treatment of 
cardiovascular risk factors [5-7], control of both serum lipid levels and blood pressure (BP) 
remains suboptimal [8-13]. 
 
As part of the recent European Study on Cardiovascular Risk Prevention and Management in 
Usual Daily Practice (EURIKA; ClinicalTrials.gov identifier: NCT00882336), a study of the 
primary prevention of CVD in Europe, we have shown that only 41.2% of patients with no 
history of CVD and being treated for dyslipidaemia attained both total cholesterol and low-
density lipoprotein cholesterol (LDL-C) targets of <5 and <3 mmol/L, respectively [8]. 
Similarly, only 38.8% of these patients being treated for hypertension achieved the BP target 
of <140/90 mmHg, as recommended by the most recent European guidelines [14]. The high 
proportion of patients unable to achieve satisfactory control of both serum lipid levels and 
hypertension suggests that there may be an interaction between the two risk factors. Indeed, 
several studies have shown that there may be a positive association between elevated serum 
lipid levels and hypertension [15,16] and that better lipid control may lead to a lower 
incidence of new-onset hypertension [17,18]. 
 
Statins are the mainstay of cholesterol-lowering drug therapy. Although the primary function 
of statins is to reduce cholesterol levels, it has been suggested that they may also have a mild, 
but clinically relevant, BP-lowering effect, particularly in patients with poorly controlled 
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hypertension [19-21]. Moreover, several pathophysiological mechanisms may account for the 
association between BP and serum lipid profile, including overexpression of angiotensin II 
type 1 (AT1) receptors and non-angiotensin-converting enzyme (non-ACE)-mediated 
upregulation of angiotensin II production as a result of elevated serum lipid levels [22-25]. 
 
Although several studies have reported an association between BP and serum lipid levels, 
most were published more than 10 years ago [15,26,27], included small numbers of 
individuals [16,18,27], were conducted in specific countries or cities [1,15,16,18,26,27], did 
not stratify the results according to statin treatment status [1,15,16,18,26] or were 
population based and did not focus on the clinical setting [1,15,16,18,27]. In order to 
provide a contemporary and comprehensive assessment of the association between BP and 
dyslipidaemia in usual clinical practice across several European countries in patients with 
varying degrees of CVD risk, we performed a secondary analysis of data from EURIKA. 
 
METHODS 
 
 
Study design and participants 
 
 
EURIKA was conducted in 12 European countries (Austria, Belgium, France, Germany, 
Greece, Norway, Russia, Spain, Sweden, Switzerland, Turkey and the United Kingdom) [8]. 
Data collection started in May 2009 and ended in January 2010, with a 3-month data-
collection period for each country. The study protocol was approved by the appropriate 
clinical research ethics committee in each participating country, and all patients provided 
signed informed consent. The methods for the study have been reported in detail elsewhere 
[28]. Briefly, the study recruited patients with at least one risk factor for CVD, but no history 
of cardiovascular events. The study sample was selected in a two-step process that involved 
recruitment of physicians and their patients [28,29]. In the first stage, a random sample of 
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primary care physicians and specialists involved in CVD prevention, stratified by age, sex 
and specialty, were selected for invitation to participate using the OneKey database 
(Cegedim Dendrite, Boulogne-Billancourt, France). The percentage of participating 
physicians among those invited was 7.9% [28]. In all countries, primary care physicians were 
the predominant type of physician, making up 64% of physicians overall [28]. In total, 809 
physicians (approximately 60 per country) agreed to participate in EURIKA [29]. In the 
second stage, participating physicians sequentially invited patients who met the selection 
criteria (age 50 years or older, free of CVD but having at least one major cardiovascular risk 
factor [8]. The major cardiovascular risk factors were: dyslipidaemia; hypertension; smoking 
(current or former smoker, with >100 cigarettes smoked in lifetime); diabetes mellitus 
(fasting plasma glucose ≥7.0 mmol/L [126 mg/dL] or receiving antidiabetic medication 
[insulin or oral medications]); obesity (body mass index [BMI] ≥30 kg/m
2
 or waist 
circumference ≥102 cm in men and ≥88 cm in women) [28]. Approximately 12,300 patients 
were invited to participate, of whom 7641 (about 600 patients per country) accepted [8]. 
 
Assessment of CVD risk factors 
 
 
Demographic information and other details of participating patients were gathered from 
medical records and patient interviews. For each patient, a physical examination was 
conducted, BP was measured, and a 12-hour fasting blood sample was collected within 1 
day of the initial outpatient consultation. 
 
BP measurements were obtained under standardized conditions, using calibrated mercury 
sphygmomanometers or validated automated devices and appropriate-sized cuffs. The mean 
of three consecutive measurements in the sitting position and spaced 1–2 minutes apart was 
used for the analyses [14]. Blood sample analysis was performed by a central laboratory 
(BioAnalytical Research Corporation, Ghent, Belgium) for samples from all patients except 
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those in Russia (approximately 5% of all patients), for which laboratory analysis 
was conducted locally. 
 
High-density lipoprotein cholesterol (HDL-C) concentration was measured by a modified 
enzymatic method and total cholesterol concentration by the glycerophosphate oxidase– 
peroxidase-4-aminophenazone (GPO–PAP) method (using the Roche Modular P Chemistry 
Analyzer [Roche Diagnostics, Indianapolis, IN, USA]). LDL-C concentration was 
calculated by the Friedewald formula [30]. Apolipoprotein A1 (apo-A1) and apolipoprotein 
B (apo-B) concentrations were measured using immunoturbidimetric methods. 
 
Definition of blood pressure and serum lipid level status 
 
 
BP status was defined as follows: normotensive (systolic BP [SBP] <120 mmHg and 
diastolic BP [DBP] <80 mmHg and not receiving antihypertensive medication); normal-to-
high-normal BP (SBP 120 to <140 mmHg and DBP 80 to <90 mmHg and not receiving 
antihypertensive medication); hypertensive (SBP ≥140 mmHg and/or DBP ≥90 mmHg or 
being treated with one or more antihypertensive drugs) [31]. 
 
Patients were defined as having dyslipidaemia if they had a serum LDL-C concentration 
 
≥4.9 mmol/L (190 mg/dL), a serum HDL-C concentration <1.0 mmol/L (40 mg/dL) for men 
or <1.3 mmol/L (50 mg/dL) for women, a serum non-HDL-C concentration ≥5.2 mmol/L 
(200 mg/dL) for men or ≥4.9 mmol/L (190 mg/dL) for women, or if they were receiving 
lipid-lowering medication [32]. 
 
Statistical analyses 
 
 
Statistical analyses were performed using SAS V9.2 (SAS Institute, Inc., Cary, NC, USA). 
Associations between BP (SBP, DBP and pulse pressure) and serum lipid levels were 
assessed using multivariate linear regression analyses. In a first model (model A), estimates 
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were adjusted for age, sex and BMI. Associations were also assessed with a model further 
adjusted for statin use, antihypertensive treatment (yes/no), number of cardiovascular risk 
factors (among smoking, diabetes and dyslipidaemia), physical activity and country (model 
B). Statistical significance was defined as two-sided P <0.05. For analyses stratified by 
statin use, estimates were adjusted for model A variables plus antihypertensive treatment 
(yes/no), physical activity and country. 
 
RESULTS 
 
 
Patient demographics and general characteristics 
 
 
The characteristics of the 7641 patients in the EURIKA study population are presented in 
Table 1. The mean age of subjects was 63.2 years, and there were more women (51.6%) than 
men (48.4%). The overall proportion of patients with hypertension was 72.8%, with a notable 
difference between countries (Supplementary Table 1). The countries with the highest and the 
lowest proportions of individuals with hypertension were Sweden (82.2%) and Austria 
(61.4%), respectively. Overall, 5239 patients (68.6%) were receiving antihypertensive 
medications, with the most common treatments being diuretics, angiotensin II antagonists and 
ACE inhibitors (Table 2). 
 
The prevalence of dyslipidaemia was 64.8%, with a between-countries range of 57.5%– 
73.7%. Austria had the lowest proportion of patients with dyslipidaemia and Greece the 
highest. Patients with both hypertension and dyslipidaemia accounted for 47.0% of the 
study participants (between-countries range: 41.0%–58.4%). The mean serum 
concentrations of LDL-C, HDL-C, total cholesterol and apo-B were 3.2, 1.4 and 5.5 mmol/L 
and 0.9 g/L, respectively. 
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Relationship between blood pressure and serum lipid profile 
 
 
In order to determine the relationship between BP (SBP and DBP) and serum lipid levels 
(LDL-C, HDL-C, non-HDL-C, total cholesterol, apo-A1 and apo-B), scatterplots with 
regression lines were created for all patients for whom data were available (Figures 1 and 2). 
When adjusted for age, sex and BMI, linear regression analyses (model A) showed that 
LDL-C, non-HDL-C, total cholesterol, apo-A1 and apo-B levels were significantly 
associated with SBP, and that LDL-C, non-HDL-C, total cholesterol and apo-B levels were 
significantly associated with DBP (Table 3). Similar results were observed when the 
regression analyses were further adjusted for use of statins, antihypertensive treatment, 
number of cardiovascular risk factors, physical activity and study country (model B). 
 
When stratifying the analyses by statin use, the aforementioned associations, adjusted for age, 
sex, BMI, antihypertensive treatment, physical activity and study country, remained 
significant, and the associations between apo-A1 and DBP in patients not treated with a statin 
became significant (Table 4). 
 
Relationship between pulse pressure and serum lipid profile 
 
 
Scatterplots with regression lines were created to determine the relationship between pulse 
pressure (SBP minus DBP) and serum lipid levels (Figure 3). Linear regression analyses 
adjusted for model B showed that HDL-C, total cholesterol and apo-A1 were significantly 
associated with pulse pressure (Table 5). When stratifying the analyses by statin use, none of 
the aforementioned associations, adjusted for age, sex, BMI, antihypertensive treatment, 
physical activity and study country, remained significant when only patients treated with 
statins were considered. The associations between total cholesterol, apo-A1 and pulse 
pressure remained significant when only patients not treated with statins were considered 
(Table 5). 
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DISCUSSION 
 
 
The present study has shown a small but statistically significant positive association between 
serum lipid levels (LDL-C, total cholesterol, non-HDL-C and apo-B) and BP in a large 
sample of patients with at least one risk factor for CVD but no history of CVD who were 
enrolled in a setting of day-to-day clinical practice. The relationship between BP and serum 
lipid profile involves both SBP and DBP, and is independent of statin use, antihypertensive 
treatment and number of cardiovascular risk factors. A similar association has been 
previously described in both the Tromsø Study [15] and the Brisighella Heart Study [16]. 
The Tromsø Study showed that non-HDL-C levels increased significantly with increasing 
SBP and DBP [15]. Similarly, in the Brisighella Heart Study, LDL-C and apo-B serum levels 
appeared to be significantly related to SBP and DBP [16]. For example, in a model adjusted 
for age, sex, BMI, smoking habit, physical activity level and serum creatinine, apo-B 
appeared to be significantly positively related to both SBP (unstandardized coefficient 0.166 
mmHg/mg/dL; 95% confidence interval [CI] 0.133 to 0.198; P < 0.001) and DBP 
(unstandardized coefficient 0.071 mmHg/mg/dL; 95% CI 0.051 to 0.090; P < 0.001). 
Analogously, in EUROASPIRE III, a survey of patients previously hospitalized for coronary 
heart disease, a negative association was observed between dyslipidaemia and BP control in 
individuals using antihypertensive medication [33]. Our results are also in line with recent 
findings that higher LDL-C levels are associated with a higher incidence of new-onset 
hypertension [17,18]. These data support the hypothesis that dyslipidaemia may contribute 
significantly to the onset and progression of hypertension. 
 
The association between serum lipid levels and BP is corroborated by the results of a recent 
meta-analysis of 40 prospective controlled studies involving a total of 45,113 patients, which 
showed a small reduction in mean SBP (2.62 mmHg; 95% CI 1.84 to 3.41; P < 0.001) and in 
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mean DBP (0.94 mmHg; 95% CI 0.57 to 1.31; P < 0.001) in patients treated with statins 
compared with those not treated with statins [19]. The positive effect of statins on BP was 
slightly greater in hypertensive patients than in normotensive patients. Furthermore, a recent 
study that included data from two separate interventional studies in hypertensive and diabetic 
individuals consistently showed that statin use was associated with lower BP and reduced 
aldosterone levels [21]. Lower aldosterone levels at higher statin doses indicated a dose– 
response effect for statin use [21]. Additionally, ex vivo experiments confirmed that statins 
blocked potassium-stimulated production of aldosterone, suggesting that statins act 
downstream from the AT1 receptor to decrease aldosterone production [21]. 
 
From a practical point of view, the BP changes associated with the modifications of serum 
lipid profile can have a measurable impact on cardiovascular risk profile [14]. A BP increase 
of a few mmHg in the general population has been associated with an increase in the risk of 
fatal and non-fatal coronary artery disease and stroke in both normotensive and hypertensive 
patients [34]. Conversely, a reduction in BP of the magnitude observed in patients under 
statin treatment may have a significant impact on the prevention of CVD at a population 
level. Results from an overview of observational studies and randomized trials suggest that a 
2 mmHg reduction in DBP would result in a 17% decrease in the prevalence of hypertension 
as well as a 6% reduction in the risk of coronary heart disease and a 15% reduction in the risk 
of stroke and transient ischaemic attack [35]. These findings highlight the importance of 
improving lipid control in the general population, with the aim of reducing the burden of 
CVD attributable to elevated BP. 
 
Several pathophysiological mechanisms have been suggested to explain the observed 
association between dyslipidaemia and hypertension. A potential explanation is that elevated 
LDL-C levels can progressively impair endothelial function and promote vascular stiffness, 
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thus leading to an increase in BP. Patients in EURIKA were free of overt CVD, and the 
possibility of a high prevalence of atherosclerotic disease in this population is unlikely. 
However, total cholesterol and apo-A1 were significantly associated with pulse pressure 
overall and in patients not treated with statins, although not in patients treated with statins. 
Alternatively, more complex mechanisms may explain the effect of dyslipidaemia on BP. In 
particular, several studies have suggested that high levels of LDL-C may increase instability 
of mRNA for AT1 receptors [22,36,37], leading to overexpression of AT1 receptors in 
vascular tissues. Activation of these receptors by angiotensin II results in an enhanced 
vasoconstrictive response that might contribute to the development of hypertension and 
atherosclerotic disease, an effect has also been described in vivo [38-40]. In addition, 
angiotensin II promotes the oxidation of LDL-C, with increased levels of oxidized LDL-C 
also contributing to overexpression of AT1 receptors [41]. Beyond direct effects of LDL-C 
on AT1 receptors, it has also been suggested that dyslipidaemia may increase the chymase-
dependent production of angiotensin II [24,42]. This increase in ACE-independent 
production of angiotensin II may act synergistically with upregulation of AT1 receptors in 
hypercholesterolaemic patients, which would explain the observed correlation between serum 
lipid levels and BP. 
 
Regardless of the mechanism involved, the evidence of a significant association between 
elevated LDL-C and BP highlights the importance of controlling serum lipid levels in the 
general population and in patients with hypertension in particular, who may benefit from 
a more intensive statin treatment regimen. 
 
Strengths and limitations 
 
 
Particular strengths of our study include a large sample of patients from multiple countries, 
the collection of data with standardized procedures and a reliable data set provided by the use 
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of a central laboratory for analyses of serum lipid levels. A limitation inherent in the 
observational study design is that the causal contributions of pathophysiological mechanisms 
are not elucidated. Furthermore, the cross-sectional design of the study does not allow the 
direction of the association between serum lipid levels and BP to be established. It should 
also be noted that in linear regression analyses, several parameters that may affect BP and/or 
serum lipid levels, such as dietary habits, were not taken into account. Also, although 
analyses were adjusted for antihypertensive treatment (yes/no) and for number of 
cardiovascular risk factors, they were not adjusted separately for class of antihypertensive 
treatment or type of cardiovascular risk factor, and relationships between BP and lipid levels 
were not assessed separately in hypertensive participants. Furthermore, information on 
medication adherence was not available and could thus not be taken into consideration. 
Although further research is required to determine whether there is a causal relationship 
between serum lipid levels and BP, our results suggest that dyslipidaemia should be carefully 
assessed and managed in patients with hypertension. 
 
CONCLUSION 
 
 
In this study, we have observed a significant association between serum lipid levels and BP 
in a large, multinational, European, primary CVD prevention population. Our results are in 
agreement with those of previously conducted studies [15,16]. Given the high concomitant 
prevalence of hyperlipidaemia and hypertension observed in this and other studies [2,3], 
further research is warranted to assess the BP-lowering effect of statins in addition to 
standard hypertensive treatment and to develop more effective multidisciplinary management 
of patients with both dyslipidaemia and hypertension. 
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TABLE 1. Socio-demographic and clinical characteristics of patients in EURIKA 
(N = 7641) 
 
Characteristic Overall (N = 7641) 
  
Age (years) 63.2 (9.0) 
Sex   
Men, n (%) 3696 (48.4) 
Women, n (%) 3945 (51.6) 
SBP (mmHg) 135.1 (16.6) 
DBP (mmHg) 80.9 (9.9) 
Normotensive, n (%) 701 (9.2) 
Normal-to-high-normal BP, n (%) 1359 (17.9) 
Hypertensive, n (%) 5559 (72. 8) 
Dyslipidaemia, n (%) 4948 (64.8) 
Hypertension and dyslipidaemia, n (%) 3593 (47.0) 
LDL-C (mmol/L) 3.2 (1.0) 
HDL-C (mmol/L) 1.4 (0.4) 
Non-HDL-C (mmol/L) 4.0 (1.1) 
TC (mmol/L) 5.5 (1.1) 
Apo-A1 (g/L) 1.5 (0.3) 
Apo-B (g/L) 0.9 (0.2) 
 
 
Data are mean (SD) unless otherwise stated. Apo-A1, apolipoprotein A1; Apo-B, 
apolipoprotein B; BP, blood pressure; DBP, diastolic blood pressure; EURIKA, European 
Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice; HDL-
C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, 
systolic blood pressure; SD, standard deviation; TC, total cholesterol. 
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TABLE 2. Treatment characteristics in patients in EURIKA receiving antihypertensive 
 
treatment (n = 5239) 
 
 
 Patients receiving 
 antihypertensive treatment 
 (n = 5239) 
   
Number of antihypertensive drugs   
1 2041 (39.0) 
2 1903 (36.3) 
3 920 (17.6) 
≥ 4 375 (7.1) 
Type of antihypertensive drug   
Angiotensin II antagonists 2121 (40.5) 
Anti-adrenergic agents 27 (0.5) 
Beta-blocking agents 1787 (34.1) 
Calcium channel blockers 1560 (29.8) 
Diuretics 2397 (45.8) 
ACE inhibitors 1912 (36.5) 
Alpha-adrenergic antagonist 166 (3.2) 
Other antihypertensive agent 223 (4.3) 
 
 
Data are n (%). ACE, angiotensin-converting enzyme; EURIKA, European Study on 
Cardiovascular Risk Prevention and Management in Usual Daily Practice. 
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TABLE 3. Relationship between blood pressure and serum lipid profile for patients in EURIKA 
 
 
  Model A
a
   Model B
b
  
     
 Regression coefficient  Regression coefficient  
   P value
c
   P value
c
 
  (95% CI)   (95% CI)  
       
Association with SBP       
LDL-C 0.93 (0.54 to 1.31)
d
 <0.0001 0.95 (0.56 to 1.34)
d
 <0.0001 
HDL-C –0.21 (–1.20 to 0.78)
d
 0.6786 0.40 (–0.57 to 1.38)
d
 0.4161 
Non-HDL-C 1.07 (0.73 to 1.40)
d
 <0.0001 1.06 (0.72 to 1.39)
d
 <0.0001 
Total cholesterol 1.02 (0.69 to 1.35)
d
 <0.0001 1.08 (0.75 to 1.41)
d
 <0.0001 
Apo-A1 1.66 (0.23 to 3.10)
e
 0.0233 2.45 (1.04 to 3.85)
e
 0.0006 
Apo-B 4.94 (3.43 to 6.46)
e
 <0.0001 4.85 (3.35 to 6.35)
e
 <0.0001 
Association with DBP       
LDL-C 0.96 (0.73 to 1.19)
d
 <0.0001 0.85 (0.61 to 1.09)
d
 <0.0001 
HDL-C –0.50 (–1.09 to 0.10)
d
 0.1012 –0.42 (–1.01 to 0.17)
d
 0.0922 
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Non-HDL-C 0.95 (0.75 to 1.15)
d
 <0.0001 0.88 (0.67 to 1.08)
d
 <0.0001 
Total cholesterol 0.87 (0.67 to 1.07)
d
 <0.0001 0.81 (0.61 to 1.01)
d
 <0.0001 
Apo-A1 0.34 (–0.52 to 1.20)
e
 0.4371 0.60 (–0.25 to 1.45) 
e
 0.1674 
Apo-B 4.33 (3.42 to 5.23)
e
 <0.0001 4.04 (3.14 to 4.95) 
e
 <0.0001 
 
Apo-A1, apolipoprotein A1; Apo-B, apolipoprotein B; BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; EURIKA, 
European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice; HDL-C, high-density lipoprotein cholesterol; 
LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure. 
 
a
Linear regressions adjusted for sex, age and BMI. 
 
b
Linear regressions adjusted for sex, age, BMI, statin use, antihypertensive treatment (yes/no), number of cardiovascular risk factors 
(0/1/2/3 among dyslipidaemia, smoking and diabetes), physical activity and country. 
 
c
Significant P values (<0.05) in bold. 
 
d
mmHg/mmol/L. 
 
e
mmHg/g/L. 
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TABLE 4. Relationship between blood pressure and serum lipid profile for patients in EURIKA treated and not treated with a statin 
 
 Without statin (n = 4601) With statin (n = 3040) 
 
 SBP  DBP SBP DBP 
 
      
 
 
LDL-C 1.01 (0.49 to 1.53)
a,b
 0.72 (0.41 to 1.04)
a,b
 0.94 (0.35 to 1.52)
a,b
 1.05 (0.70 to 1.41)
a,b
 
 
HDL-C 0.09 (–1.16 to 1.34)
a,b
 –0.61 (–1.37 to 0.14)
a,b
 1.10 (–0.43 to 2.63)
a,b
 0.40 (–0.54 to 1.34)
a,b
 
 
Non-HDL-C 1.08 (0.63 to 1.53)
a,b
 0.79 (0.53 to 1.07)
a,b
 1.06 (0.57 to 1.55)
a,b
 0.93 (0.63 to 1.23)
a,b
 
 
Total cholesterol 1.08 (0.63 to 1.53)
a,b
 0.71 (0.44 to 0.98)
a,b
 1.13 (0.65 to 1.62)
a,b
 0.94 (0.64 to 1.24)
a,b
 
 
Apo-A1 2.18 (0.35 to 4.01)
a,c
 0.35 (–0.76 to 1.45)
a,c
 2.84 (0.65 to 5.02)
a,c
 1.35 (0.01 to 2.69)
a,c
 
 
Apo-B 4.59 (2.59 to 6.59)
a,c
 3.46 (2.26 to 4.67)
a,c
 5.33 (3.07 to 7.59)
a,c
 4.56 (3.18 to 5.93)
a,c
 
 
 
Numbers in bold are statistically significant (P < 0.05). Apo-A1, apolipoprotein A1; Apo-B, apolipoprotein B; BMI, body mass index; DBP, 
diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure. 
a
Regression coefficient (95% confidence intervals) analysis adjusted for age, sex, BMI, antihypertensive treatment (yes/no), physical activity 
and country. 
 
b
mmHg/mmol/L. 
 
c
mmHg/g/L. 
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TABLE 5. Relationship between pulse pressure and serum lipid profile for patients in EURIKA treated and not treated with a statin 
 
 Overall (N = 7641) Without statin (n = 4601) With statin (n = 3040) 
    
LDL-C 0.09 (–0.22 to 0.41)
a,c
 0.28 (–0.13 to 0.69)
b,c
 –0.12 (–0.60 to 0.36)
b,c
 
HDL-C 0.83 (0.05 to 1.61)
a,c
 0.70 (–0.28 to 1.69)
b,c
 0.71 (–0.55 to 1.96)
b,c
 
Non-HDL-C 0.18 (–0.09 to 0.45)
a,c
 0.28 (–0.08 to 0.64)
b,c
 0.13 (–0.28 to 0.53)
b,c
 
Total cholesterol 0.27 (0.01 to 0.54)
a,c
 0.37 (0.01 to 0.72)
b,c
 0.19 (–0.20 to 0.59)
b,c
 
Apo-A1 0.57 (0.73 to 2.98)
a,d
 1.83 (0.38 to 3.27)
b,d
 1.51 (–0.28 to 3.30)
b,d
 
Apo-B 0.78 (–0.42 to 1.98)
a,d
 1.09 (–0.49 to 2.67)
b,d
 0.76 (–1.09 to 2.62)
b,d
 
 
Numbers in bold are statistically significant (P < 0.05). Apo-A1, apolipoprotein A1; Apo-B, apolipoprotein B; BMI, body mass index; DBP, 
diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood 
pressure. 
a
Regression coefficient (95% confidence intervals) analysis adjusted for sex, age, BMI, statin use, antihypertensive treatment (yes/no), 
number of cardiovascular risk factors (0/1/2/3 among dyslipidaemia, smoking and diabetes), physical activity and country. 
 
b
Regression coefficient (95% confidence intervals) analysis adjusted for age, sex, BMI, antihypertensive treatment (yes/no), physical activity 
and country. 
 
c
mmHg/mmol/L. 
 
d
mmHg/g/L. 
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SUPPLEMENTARY TABLE 1. Socio-demographic and clinical characteristics of patients in EURIKA by country 
 
 Aus Bel Fra Ger Gre Nor Rus Spa Swe Swi Tur UK 
 (n = 624) (n = 638) (n = 593) (n = 678) (n = 620) (n = 611) (n = 604) (n = 642) (n = 628) (n = 667) (n = 663) (n = 673) 
             
Age, mean (SD) 61.9 (8.6) 64.6 (8.9) 64.1 (8.8) 65.3 (8.8) 65.3 (8.9) 62.9 (8.8) 58.3 (7.3) 63.1 (9.0) 64.9 (8.6) 65.2 (9.9) 59.4 (7.6) 65.0 (8.9) 
Sex, n (%)             
Men 297 (47.6) 312 (48.9) 325 (54.8) 333 (49.1) 285 (46.0) 298 (48.8) 192 (31.8) 330 (51.4) 315 (50.2) 352 (52.8) 313 (47.2) 344 (51.1) 
Women 327 (52.4) 326 (51.1) 268 (45.2) 345 (50.9) 335 (54.0) 313 (51.2) 412 (68.2) 312 (48.6) 313 (49.8) 315 (47.2) 350 (52.8) 329 (48.9) 
Hypertension,
a
 n (%) 447 (61.4) 448 (70.2) 434 (73.2) 549 (81.0) 413 (66.6) 426 (69.7) 486 (80.5) 435 (67.8) 516 (82.2) 475 (71.2) 441 (66.5) 489 (72.7) 
Dyslipidaemia,
b
 n (%) 359 (57.5) 427 (66.9) 361 (60.9) 412 (60.8) 457 (73.7) 401 (65.6) 423 (70.0) 436 (67.9) 397 (63.2) 433 (64.9) 395 (59.6) 447 (66.4) 
Hypertension and 269 (43.1) 292 (45.8) 262 (44.2) 334 (49.3) 301 (48.5) 275 (45.0) 353 (58.4) 290 (45.2) 328 (52.2) 294 (44.1) 272 (41.0) 323 (48.0) 
dyslipidaemia, n (%)              
Aus, Australia; Bel, Belgium; DBP, diastolic blood pressure; EURIKA, European Study on Cardiovascular Risk Prevention and Management in 
Usual Daily Practice; Fra, France; Ger, Germany; Gre, Greece; HDL-C, high-density lipoprotein; LDL-C, low-density lipoprotein; Nor, 
Norway; Rus, Russia; SBP, systolic blood pressure; Spa, Spain; Swe, Sweden; Swi, Switzerland; Tur, Turkey; UK, United Kingdom. 
 
a
SBP ≥140 mmHg and/or DBP ≥90 mmHg or being treated with one or more antihypertensive drugs. 
 
b
LDL-C concentration ≥4.9 mmol/L (190 mg/dL), a serum HDL-C concentration <1.0 mmol/L (40 mg/dL) for men or <1.3 mmol/L (50 
mg/dL) for women, a non-HDL-C concentration ≥5.2 mmol/L (200 mg/dL) for men or ≥4.9 mmol/L (190 mg/dL) for women, or receiving 
lipid-lowering medication 
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FIGURE LEGENDS 
 
 
 
 
FIGURE 1 Scatterplots of patients’ systolic blood pressure and lipid levels, according to 
statin treatment. Dotted and solid lines represent regression lines for non-users and users of 
statins, respectively. Apo-A1, apolipoprotein A1; Apo-B, apolipoprotein B; HDL-C, high-
density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic 
blood pressure. 
 
 
FIGURE 2 Scatterplots of patients’ diastolic blood pressure and lipid levels, according to 
statin treatment. Dotted and solid lines represent regression lines for non-users and users of 
statins, respectively. Apo-A1, apolipoprotein A1; Apo-B, apolipoprotein B; DBP, diastolic 
blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein 
cholesterol. 
 
 
FIGURE 3 Scatterplots of patients’ pulse pressure and lipid levels, according to statin 
treatment. Dotted and solid lines represent regression lines for non-users and users of 
statins, respectively. Apo-A1, apolipoprotein A1; Apo-B, apolipoprotein B; DBP, diastolic 
blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 
lipoprotein cholesterol. 
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